1. Academic Validation
  2. A systematic investigation on animal models of cyclosporine A combined with Escherichia coli to simulate the immunosuppressive status of sepsis patients before onset

A systematic investigation on animal models of cyclosporine A combined with Escherichia coli to simulate the immunosuppressive status of sepsis patients before onset

  • Int Immunopharmacol. 2018 Sep;62:67-76. doi: 10.1016/j.intimp.2018.05.031.
Xianbin Kong 1 Jingjing Zhang 2 Jingrui Huo 2 Lei Wang 2 Lei Guo 3 Ying Liu 2 Tao He 4 Zhonglei Sun 5 Xuyi Chen 4 Zhenjiang Hou 2 Xiaohui Yang 2 Yi Tian 2 Shizhong Sun 4 Feng Chen 6 Yingfu Liu 7
Affiliations

Affiliations

  • 1 Graduate School of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.
  • 2 Science and Technology Experiment Center of Cangzhou Medical College, Cangzhou 061001, China.
  • 3 Brain Hospital of Cangzhou Central Hospital, Cangzhou 061001, China.
  • 4 Affiliated Hospital of Logistics University of Chinese People's Armed Police Forces, Tianjin 300163, China.
  • 5 Graduate School of Jinzhou Medical University, Jinzhou 121000, China.
  • 6 Science and Technology Experiment Center of Cangzhou Medical College, Cangzhou 061001, China. Electronic address: chenfeng_tj@126.com.
  • 7 Science and Technology Experiment Center of Cangzhou Medical College, Cangzhou 061001, China. Electronic address: liu_yingfu@126.com.
Abstract

Immunosuppression is an important mechanism for the development of sepsis pathology, and is the key to the high mortality of sepsis. However, patients appear to be immunocompromised before sepsis onset due to lack of enough attention. Present sepsis models cannot fully mimic the onset of sepsis in patients. Hence, effective treatments in animal experiments could not be transformed into clinical application. In the present study, we improved the animal model of sepsis and used cyclosporine A immunosuppressive mice to make it closer to immune status before the onset of sepsis, followed by the intraperitoneal injection of Escherichia coli (E. coli) CMCC (B) 44,102 standard strain to produce the immunocompromised sepsis model. This trial systematically evaluates the new immunosuppressive sepsis model. Compared with routine sepsis models, the release of inflammatory factors in the new sepsis model was insufficient, blood bacteria were more cultured, diffuse intravascular coagulation (DIC) was more severe, lung, liver and kidney damage were heavier, and mortality rate was higher. In conclusion, the new sepsis model can mimic the patient's pre-onset immunocompromised state, is suitable for the development and evaluation of new methods of sepsis, and solves the controversy of sepsis treatment, providing new ideas and direction.

Keywords

Animal model; Cyclosporine A; Escherichia coli; Immunosuppressive; Sepsis.

Figures
Products